372 related articles for article (PubMed ID: 29470570)
1. A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification.
Mehralivand S; Shih JH; Rais-Bahrami S; Oto A; Bednarova S; Nix JW; Thomas JV; Gordetsky JB; Gaur S; Harmon SA; Siddiqui MM; Merino MJ; Parnes HL; Wood BJ; Pinto PA; Choyke PL; Turkbey B
JAMA Oncol; 2018 May; 4(5):678-685. PubMed ID: 29470570
[TBL] [Abstract][Full Text] [Related]
2. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
3. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
5. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
[TBL] [Abstract][Full Text] [Related]
6. 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies.
Piert M; Montgomery J; Kunju LP; Siddiqui J; Rogers V; Rajendiran T; Johnson TD; Shao X; Davenport MS
J Nucl Med; 2016 Jul; 57(7):1065-70. PubMed ID: 26985061
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study.
Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Winther MD; Jakobsen H; Thomsen HS
JAMA Netw Open; 2018 Jun; 1(2):e180219. PubMed ID: 30646066
[TBL] [Abstract][Full Text] [Related]
8. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
9. Defining the learning curve for multiparametric magnetic resonance imaging (MRI) of the prostate using MRI-transrectal ultrasonography (TRUS) fusion-guided transperineal prostate biopsies as a validation tool.
Gaziev G; Wadhwa K; Barrett T; Koo BC; Gallagher FA; Serrao E; Frey J; Seidenader J; Carmona L; Warren A; Gnanapragasam V; Doble A; Kastner C
BJU Int; 2016 Jan; 117(1):80-6. PubMed ID: 25099182
[TBL] [Abstract][Full Text] [Related]
10. A clinical prediction tool to determine the need for concurrent systematic sampling at the time of magnetic resonance imaging-guided biopsy.
Sathianathen NJ; Warlick CA; Weight CJ; Ordonez MA; Spilseth B; Metzger GJ; Murugan P; Konety BR
BJU Int; 2019 Apr; 123(4):612-617. PubMed ID: 30417504
[TBL] [Abstract][Full Text] [Related]
11. High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens.
Steurer S; Rico SD; Simon R; Minner S; Tsourlakis MC; Krech T; Koop C; Graefen M; Heinzer H; Adam M; Huland H; Schlomm T; Sauter G; Lumiani A
BJU Int; 2017 Sep; 120(3):365-376. PubMed ID: 28295933
[TBL] [Abstract][Full Text] [Related]
12. In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?
Salami SS; Ben-Levi E; Yaskiv O; Ryniker L; Turkbey B; Kavoussi LR; Villani R; Rastinehad AR
BJU Int; 2015 Apr; 115(4):562-70. PubMed ID: 25252133
[TBL] [Abstract][Full Text] [Related]
13. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer.
Kuru TH; Roethke MC; Seidenader J; Simpfendörfer T; Boxler S; Alammar K; Rieker P; Popeneciu VI; Roth W; Pahernik S; Schlemmer HP; Hohenfellner M; Hadaschik BA
J Urol; 2013 Oct; 190(4):1380-6. PubMed ID: 23608676
[TBL] [Abstract][Full Text] [Related]
14. Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis.
Schoots IG; Nieboer D; Giganti F; Moore CM; Bangma CH; Roobol MJ
BJU Int; 2018 Dec; 122(6):946-958. PubMed ID: 29679430
[TBL] [Abstract][Full Text] [Related]
15. [Real-time MRI/US fusion-guided biopsy in biopsy-naïve and pre-biopsied patients with suspicion for prostate cancer].
Maxeiner A; Stephan C; Fischer T; Durmus T; Kilic E; Asbach P; Haas M; Günzel K; Neymeyer J; Miller K; Cash H
Aktuelle Urol; 2015 Jan; 46(1):34-8. PubMed ID: 25519051
[TBL] [Abstract][Full Text] [Related]
16. Detection of significant prostate cancer with magnetic resonance targeted biopsies--should transrectal ultrasound-magnetic resonance imaging fusion guided biopsies alone be a standard of care?
Delongchamps NB; Lefèvre A; Bouazza N; Beuvon F; Legman P; Cornud F
J Urol; 2015 Apr; 193(4):1198-204. PubMed ID: 25451824
[TBL] [Abstract][Full Text] [Related]
17. Refining the risk-stratification of transrectal biopsy-detected prostate cancer by elastic fusion registration transperineal biopsies.
Covin B; Roumiguié M; Quintyn-Ranty ML; Graff P; Khalifa J; Aziza R; Ploussard G; Portalez D; Malavaud B
World J Urol; 2019 Feb; 37(2):269-275. PubMed ID: 30145777
[TBL] [Abstract][Full Text] [Related]
18. An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-Preliminary experience.
Costa DN; Kay FU; Pedrosa I; Kolski L; Lotan Y; Roehrborn CG; Hornberger B; Xi Y; Francis F; Rofsky NM
Urol Oncol; 2017 Apr; 35(4):149.e15-149.e21. PubMed ID: 27939349
[TBL] [Abstract][Full Text] [Related]
19. Results of a comparative analysis of magnetic resonance imaging-targeted versus three-dimensional transrectal ultrasound prostate biopsies: Size does matter.
Peltier A; Aoun F; Albisinni S; Marcelis Q; Ledinh D; Paesmans M; Lemort M; van Velthoven R
Scand J Urol; 2016 Jun; 50(3):144-8. PubMed ID: 26754860
[TBL] [Abstract][Full Text] [Related]
20. MRI-TRUS fusion biopsy of the prostate: Quality of image fusion in a clinical setting.
Schlenker B; Apfelbeck M; Buchner A; Stief C; Clevert DA
Clin Hemorheol Microcirc; 2018; 70(4):433-440. PubMed ID: 30347605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
